The FDA granted full approval to the menin inhibitor revumenib (Revuforj) for adults and children 1 year and older with relapsed/refractory acute leukemia and a lysine methyltransferase 2A gene ( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback